PROGLAY-H® Tablets

PROGLAY-H® Tablets
Generic Name:
Estradiol Valerate + Norgestrel
Therapeutic Group:
Gynecology / Endocrinology
Drug Category:
Hormone Replacement Therapy (HRT) – Estrogen + Progestogen Combination
Content / Composition:
Each tablet contains:
* Estradiol Valerate …… 2 mg
* Norgestrel …… 0.5 mg
Indications:
Indicated for hormone-related conditions in women, including:
* Hormone Replacement Therapy (HRT) in menopause
* Relief of menopausal symptoms (hot flashes, night sweats, vaginal dryness)
* Prevention of postmenopausal osteoporosis
* Hormonal imbalance management
* Secondary amenorrhea (as per physician advice)
Dosage:
As directed by the physician.
Typical regimen:
* One tablet daily, preferably at the same time each day
* Cyclic or continuous regimen depending on clinical need
Contraindications:
* Known or suspected pregnancy
* History of breast cancer or estrogen-dependent tumors
* Undiagnosed vaginal bleeding
* Active or history of thromboembolic disorders
* Severe hepatic impairment
* Hypersensitivity to any component
Administration:
For oral use.
Swallow with water, with or without food.
Take regularly at the same time each day.
Interaction:
Use caution with:
* Enzyme-inducing drugs (rifampicin, carbamazepine, phenytoin)
* Anticoagulants
* Thyroid medications
* Herbal supplements (e.g., St. John’s Wort)
Compatibility:
Compatible with most HRT regimens under medical supervision.
Clinical monitoring recommended when combined with other hormonal therapies.
Stability / Storage:
Store below 25°C.
Protect from moisture and direct light.
Keep out of reach of children.
Precautions:
* Risk of thromboembolism (DVT, PE)
* Regular breast and pelvic examination recommended
* Monitor blood pressure
* Use lowest effective dose for shortest duration
* Caution in patients with diabetes, cardiovascular disease
* Discontinue if signs of thrombosis or liver dysfunction appear
Side Effects:
Common:
* Nausea
* Breast tenderness
* Headache
* Mood changes
Others:
* Weight changes
* Breakthrough bleeding or spotting
* Edema
Rare but serious:
* Thromboembolic events
* Stroke or myocardial infarction
* Hepatic dysfunction
Website Note (Professional):
Hormone Replacement Therapy should be initiated and monitored by a qualified healthcare professional.
Benefit-risk assessment is required before starting treatment.